BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma

BeOne Medicines Ltd ( (HK:6160) ) has provided an update.

BeOne Medicines has secured accelerated U.S. FDA approval for BEQALZI (sonrotoclax), the first and only BCL2 inhibitor indicated for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies, including a BTK inhibitor. The drug was engineered to offer enhanced potency, selectivity, and a favorable pharmacologic profile, positioning it as a next-generation backbone therapy in this high‑need setting.

The approval is based on Phase 1/2 trial data showing a 52% overall response rate, a 16% complete response rate, rapid median time to response of 1.9 months, and generally well-tolerated safety in heavily pretreated patients. As a targeted option in a rare and aggressive lymphoma with limited post-BTK choices, BEQALZI’s entry, supported by Breakthrough, Fast Track and Orphan designations, strengthens BeOne’s standing in hematologic oncology and may materially expand treatment options and hope for U.S. patients and families confronting repeated relapse.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.

More about BeOne Medicines Ltd

BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company focused on developing next-generation targeted therapies for B-cell malignancies. Its pipeline includes BCL2 inhibitors such as BEQALZI (sonrotoclax), designed to improve efficacy, tolerability, and convenience for patients with difficult-to-treat blood cancers, including mantle cell lymphoma.

Average Trading Volume: 3,898,585

Technical Sentiment Signal: Buy

Current Market Cap: HK$285B

Find detailed analytics on 6160 stock on TipRanks’ Stock Analysis page.